Literature DB >> 9819361

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.

M A Winters1, K L Coolley, Y A Girard, D J Levee, H Hamdan, R W Shafer, D A Katzenstein, T C Merigan.   

Abstract

While many point mutations in the HIV-1 reverse transcriptase (RT) confer resistance to antiretroviral drugs, inserts or deletions in this gene have not been previously characterized. In this report, 14 RT inhibitor-treated patients were found to have HIV-1 strains possessing a 6-basepair insert between codons 69 and 70 of the RT gene. Known drug resistance mutations were also observed in these strains, with T215Y appearing in all strains. Genotypic analysis indicated that the inserts had substantial nucleotide variability that resulted in relatively restricted sets of amino acid sequences. Linkage of patients' treatment histories with longitudinal sequencing data showed that insert strains appeared during drug regimens containing ddI or ddC, with prior or concurrent AZT treatment. Drug susceptibility tests of recombinant patient isolates showed reduced susceptibility to nearly all nucleoside RT inhibitors. Site- directed mutagenesis studies confirmed the role of the inserts alone in conferring reduced susceptibility to most RT inhibitors. The addition of AZT-associated drug resistance mutations further increased the range and magnitude of resistance. These results establish that inserts, like point mutations, are selected in vivo during antiretroviral therapy and provide resistance to multiple nucleoside analogs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9819361      PMCID: PMC509125          DOI: 10.1172/JCI4948

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  Mechanism of HIV-1 reverse transcriptase. Termination of processive synthesis on a natural DNA template is influenced by the sequence of the template-primer stem.

Authors:  J Abbotts; K Bebenek; T A Kunkel; S H Wilson
Journal:  J Biol Chem       Date:  1993-05-15       Impact factor: 5.157

2.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

3.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Authors:  R F Schinazi; R M Lloyd; M H Nguyen; D L Cannon; A McMillan; N Ilksoy; C K Chu; D C Liotta; H Z Bazmi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

4.  Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots.

Authors:  K Bebenek; J Abbotts; S H Wilson; T A Kunkel
Journal:  J Biol Chem       Date:  1993-05-15       Impact factor: 5.157

5.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Authors:  M Tisdale; S D Kemp; N R Parry; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

6.  Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

Authors:  P Kellam; C A Boucher; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

7.  The effects of dNTP pool imbalances on frameshift fidelity during DNA replication.

Authors:  K Bebenek; J D Roberts; T A Kunkel
Journal:  J Biol Chem       Date:  1992-02-25       Impact factor: 5.157

8.  Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.

Authors:  P L Boyer; C Tantillo; A Jacobo-Molina; R G Nanni; J Ding; E Arnold; S H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

9.  Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine.

Authors:  J E Fitzgibbon; R M Howell; C A Haberzettl; S J Sperber; D J Gocke; D T Dubin
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 10.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272

View more
  71 in total

1.  4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.

Authors:  E I Kodama; S Kohgo; K Kitano; H Machida; H Gatanaga; S Shigeta; M Matsuoka; H Ohrui; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.

Authors:  D Persaud; T Pierson; C Ruff; D Finzi; K R Chadwick; J B Margolick; A Ruff; N Hutton; S Ray; R F Siliciano
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

3.  A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.

Authors:  R A Smith; G J Klarmann; K M Stray; U K von Schwedler; R F Schinazi; B D Preston; T W North
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

4.  Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice.

Authors:  C Delaugerre; M Mouroux; A Yvon-Groussin; A Simon; F Angleraud; J M Huraux; H Agut; C Katlama; V Calvez
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries.

Authors:  R W Shafer; D R Jung; B J Betts
Journal:  Nat Med       Date:  2000-11       Impact factor: 53.440

6.  Response to antiretroviral therapy in a patient with an uncommon codon 69 insertion in the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  P Bonfanti; I Faggion; S La Seta Catamancio; M Violin; C Balotta; S Rusconi
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  G J Hanna; V A Johnson; D R Kuritzkes; D D Richman; J Martinez-Picado; L Sutton; J D Hazelwood; R T D'Aquila
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

8.  Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors.

Authors:  B Masquelier; E Race; C Tamalet; D Descamps; J Izopet; C Buffet-Janvresse; A Ruffault; A S Mohammed; J Cottalorda; A Schmuck; V Calvez; E Dam; H Fleury; F Brun-Vézinet
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

9.  Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.

Authors:  H Sato; Y Tomita; K Ebisawa; A Hachiya; K Shibamura; T Shiino; R Yang; M Tatsumi; K Gushi; H Umeyama; S Oka; Y Takebe; Y Nagai
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

10.  Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.

Authors:  Miguel E Quiñones-Mateu; Mahlet Tadele; Mariona Parera; Antonio Mas; Jan Weber; Héctor R Rangel; Bikram Chakraborty; Bonaventura Clotet; Esteban Domingo; Luis Menéndez-Arias; Miguel A Martínez
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.